Key points from article :
AgomAb Therapeutics announced €62M in series B funding round last week.
Harnessing antibodies that kickstart healing and tackle metabolic, inflammatory, and fibrotic conditions.
Funding to advance into clinical trials AgomAb’s flagship monoclonal antibody, which is inspired by the minuscule antibodies of llamas.
Mimics the action of the hepatocyte growth factor (HGF) protein.
Developing monoclonal antibodies using antibody technology to provide both stability and ability to target specific human tissues.
Global market for regenerative therapies is expected to triple between 2019 and 2025.
AgomAb’s hefty round is widely seen as a positive signal for other companies in regenerative medicine.
Ilya Pharma plans to kick off phase II testing its lead candidate in the next few months.
Novadip received a nod from the US FDA earlier this month to begin human trials of its cell therapy targeting bone regeneration.
Elastrin Therapeutics seeks to reverse cardiovascular disease using nanotechnology.
